OSE Immunotherapeutics Reports €37.7M Net Loss in 2025, Extends Cash Runway to December 2026
Event summary
- OSE Immunotherapeutics reported a net loss of €37.7M for 2025, down from a net income of €37.4M in 2024.
- Revenues plummeted from €69.9M in 2024 to €2.6M in 2025.
- The company secured €19.3M in IRIS Financing, extending its cash runway to December 2026.
- 2025 financial statements were approved on a going concern basis with significant uncertainty noted by auditors.
- The 2025 Universal Registration Document was filed with the AMF on June 3, 2026.
The big picture
OSE Immunotherapeutics' dramatic financial decline highlights the challenges faced by biotech companies in securing sustainable funding. The company's reliance on short-term financing solutions underscores the broader industry trend of volatile capital access, particularly for firms developing high-risk, high-reward therapeutic assets. The strategic focus on immuno-oncology and immuno-inflammation positions OSE within a competitive sector, but its ability to navigate financial instability will be critical to its long-term success.
What we're watching
- Cash Runway Dynamics
- Whether OSE can secure additional financing beyond December 2026 to sustain operations.
- Strategic Partnerships
- The pace at which OSE can finalize new strategic partnerships to extend its cash runway.
- Financial Stability
- How the company's ability to meet short-term financing objectives will impact its long-term viability.